The UK NICE guidelines for post-MI prophylaxis provide evidence-based recommendations that should stimulate resources to bridge the gap between current practice and guidelines.
Answers are grounded in this paper and cite their sources.
May support NICE post-MI prophylaxis recommendations in practice; leaves open refinement of specific details.
The UK National Institute for Clinical Excellence (NICE) has recently published guidelines on prophylaxis for patients who have experienced a myocardial infarction (MI). Based on a previously commissioned extensive review of the literature, the recommendations are antiplatelet therapy, beta-blockers and angiotensin converting enzyme inhibitors (ACEIs) for all patients; statins for those with hypercholesterolaemia; spironolactone for those with moderate-to-severe heart failure (HF); and insulin for those with diabetes. While there may be concerns about some of the details (eg., the possible adverse interaction between aspirin and ACEIs), comments on the use of statins for those with HF, the lack of advice on the choice of lipid-lowering therapy for those intolerent of statins, the dangers of spironolactone therapy and the practicality of intensive insulin treatment, the guidelines are firmly based on sound evidence of efficacy and cost effectiveness. The NICE guidelines should therefore stimulate the provision of resources to address the gap between current practice and these recommendations.
No takes yet. Share an insight, caveat, or question.
Kevin Fox (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: